SLU-PP-332 vs Gonadorelin
Side-by-side comparison of key properties, dosing, and research.
Recovery & RepairFat Loss & Metabolic
SLU-PP-332Sexual Health & LibidoAnti-Aging & Longevity
Gonadorelin- Summary
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- Gonadorelin is the synthetic form of endogenous GnRH (gonadotropin-releasing hormone). It stimulates the pituitary to release LH and FSH, maintaining testicular function and testosterone production. Widely used alongside TRT to prevent testicular atrophy and preserve fertility.
- Half-Life
- Not established in humans; rodent pharmacokinetics suggest hours
- ~2–4 minutes (extremely short); pulsatile dosing required to avoid desensitization
- Admin Route
- Oral (research), Subcutaneous (research)
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- Not established for humans; rodent studies used ~100 mg/kg/day
- 100 mcg
- Frequency
- Once daily in rodent studies
- Twice daily (every 12 hours)
- Key Benefits
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Maintains testicular size during TRT
- Preserves fertility and sperm production during testosterone use
- Stimulates endogenous LH/FSH production
- Maintains HPG axis function during exogenous hormone use
- Used for HCG-free TRT protocols
- Helps restart natural testosterone production (PCT)
- Side Effects
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Injection site reactions
- Headache
- Nausea at initiation
- Tachycardia (rare)
- +1 more
- Stacks With
- —
- —